Active Biotech

April 26, 2011 01:11 ET

Active Biotech's partner Teva comments on DEFINE study results in Multiple Sclerosis

LUND, SWEDEN--(Marketwire - Apr 26, 2011) -



Read Teva Pharmaceutical Industries Ltd's (NASDAQ: TEVA) complete press releasehere.

For further information on Active Biotech's and Teva's oral MS drug laquinimod, please visit www.tevapharm.com or www.activebiotech.com. .



Lund, April 26, 2011

Active Biotech AB (publ)

Tomas Leanderson
President & CEO


Active Biotech AB (STKM: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDex™ for RA. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 26, 2011, at 07:00 a.m.



Active Biotech's partner Teva comments on DEFINE : http://hugin.info/1002/R/1508761/443591.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1508761]

Contact Information

  • For further information, please contact:
    Goran Forsberg
    Vice President Investor Relations & Business Development
    Tel +46 (0)46 19 11 54